30 closest matches · ranked by relevance
Colorectal Neoplasms · Metastases · Neoplasm
Primary: Percentage of Participants With an Overall Resonse — 8.2 percentage of participants
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Colorectal Cancer
Primary: Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) — 0; 1; 0; 4 Participants
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Neoplasm Metastasis · Colorectal Cancer
Primary: Best Overall Response Rate - Independent Review Committee (IRC) — 45.6; 35.7 percentage of participants — p=0.064
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Colon Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 55 percentage of patients
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Colorectal Cancer · Metastases
Primary: Objective Tumor Response Through Week 16 — 6 participants
Metastatic Colorectal Cancer
Primary: Safety Part: Number of Subjects Experiencing DLTs (Dose Limiting Toxicity) — 0; 0; 0; 0 subjects
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Primary: Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments — 8.9; 8.0 months — p=0.0479
Esophageal Cancer · Gastric Cancer · Neoplasm Metastasis
Primary: Overall Response Rate — 0.029 proportion of paticipants
Metastatic Colorectal Cancer
Primary: Percentage of Subjects With Best Overall Confirmed Response Rate (BORR) — 54.5; 61.2 Percentage of subjects
Colorectal Cancer · Metastatic Cancer
Primary: Number of Participants With Objective Tumor Response Through Week 16 — 5 Participants
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Objective Response Rate at Weeks 17 and 25 — 20; 14; 22; 14 percentage of participants
Colorectal Cancer
Primary: Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab. — 0; 9; 10 Participants
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I) — NA
Adenomatous Polyp · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Change in ACF pERK Levels
Colon Cancer · Rectum Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Metastatic Colorectal Cancer
Primary: PFS Hazard Ratio — 0.365 months — p=0.0130
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Colorectal Cancer
Primary: Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2) — 6 Participants
Cancer
Primary: Number of Participants With Adverse Events — 3; 4; 36; 50 Participants
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Colorectal Cancer · Metastases
Primary: Progression-free Survival Time — 8.0; 7.3 weeks — p=<0.0001
Cancer of the Colon · Colon Cancer · Colon Neoplasms
Primary: Disease Control Rate — 5; 1; 0; 0 Participants
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response [PR, Objective Response Rate (ORR)] — 0.0; 4.8; 0.0 percentage of participants